@article{8a93a80f6e0a49aab11ff6df10577cab,
title = "The great debate at {"}melanoma Bridge 2018{"}, Naples, December 1st, 2018",
abstract = "The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.",
keywords = "Adjuvant, Anti-CTLA-4, Anti-PD-1, BRAF inhibitor, Immunotherapy, MEK inhibitor, Melanoma, Neoadjuvant, Targeted therapy",
author = "Ascierto, {Paolo A.} and Paolo Bruzzi and Alexander Eggermont and Omid Hamid and Tawbi, {Hussein A.} and {Van Akkooi}, Alexander and Alessandro Testori and Corrado Carac{\`o} and Igor Puzanov and Francesco Perrone",
note = "Funding Information: Paolo A. Ascierto (PAA): Consultant/advisory relationship—Bristol-Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Amgen, Array, Merck Serono, Pierre-Fabre, Incyte, NewLink Genetics, Genmab, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofy, Idera, Ultimovacs, Sandoz, Immuno-core. Research funding—Array, Bristol-Myers Squibb, Roche-Genentech. Travel Support—MSD. Paolo Bruzzi (PB): Teaching Courses, Seminars & Lectures—Pierre Fabre, Takeda, Incyte, Roche, Novartis, Eisai, Merk Serono, Ely Lilly, Sanofi, Ipsen, MSD, Bristol-Myers Squibb. Advisory Board & Consultant—AstraZeneca, MSD, Amgen, Lilly, Celgene. Alexander Eggermont (AE): Scientific advisory boards/Data monitoring committee—Bristol-Myers Squibb, GlaxoSmithKline, Incyte, ISA pharmaceuticals, IO Biotech, MedImmune, Merck-Serono, MSD, Novartis, Sanofi, Sellas and SkylineDx—Travel support—Bristol-Myers Squibb and MSD. Omid Hamid (OH): Consultant/Advisory Role: Bristol-Meyers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Amgen, Array, Merck Serono. Expert Testimony—Genentech. Other—Bristol-Meyers Squibb, Novartis, Array. Hussein A. Tawbi (HT): Research funding—Bristol-Meyers Squibb, Genentech, Merck, Celgene and GlaxoSmithKline. Consultant—Bristol-Meyers Squibb, Merck, Novartis, Genentech and Array. Alexander van Akkooi (AvA): Advisory board/consultancy—Amgen, Bristol-Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, 4SC. Research grants from Amgen, Bristol-Myers Squibb and Novartis. Alessandro Testori (AT): declares he has not conflict of interest to report. Corrado Carac{\`o} (CC): declares he has not conflict of interest to report. Igor Puzanov (IP): Consultant—Amgen, Roche, Abbvie. Publisher Copyright: {\textcopyright} 2019 The Author(s).",
year = "2019",
month = may,
day = "10",
doi = "10.1186/s12967-019-1892-5",
language = "English (US)",
volume = "17",
journal = "Journal of translational medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",
}